Onconetix, Inc. Increase Decrease In Receivable For Investment Sold
Onconetix, Inc. (ONCO) reported Increase Decrease In Receivable For Investment Sold of $154.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-11-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivableForInvestmentSold · last filed 2023-11-17
- 2023-06-30: Increase Decrease In Receivable For Investment Sold 6 month $154.00K.
| Period end | Increase Decrease In Receivable For Investment Sold 6 month |
|---|---|
| 2023-06-30 | $154.00K 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |